Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
- J. S. Frenel*
- , J. W. Kim
- , N. Aryal
- , R. Asher
- , D. Berton
- , L. Vidal
- , P. Pautier
- , J. A. Ledermann
- , R. T. Penson
- , A. M. Oza
- , J. Korach
- , T. Huzarski
- , S. Pignata
- , N. Colombo
- , T. W. Park-Simon
- , K. Tamura
- , G. S. Sonke
- , A. E. Freimund
- , C. K. Lee
- , E. Pujade-Lauraine
*Corresponding author for this work
- Institut de Cancérologie de l'Ouest
- Seoul National University
- University of Sydney
- GEICO & H Clínic de Barcelona
- Institut de Cancérologie Gustave Roussy
- University College London
- Massachusetts General Hospital
- Princess Margaret Hospital
- Pomeranian Medical University in Szczecin
- IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
- IRCCS Istituto Europeo di Oncologia - Milano
- Hannover Medical School
- National Cancer Center Japan
- Netherlands Cancer Institute
- Peter Maccallum Cancer Centre
- ARCAGY-GINECO
Research output: Contribution to journal › Article › peer-review
120
Scopus
citations